AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10348512 — intervention group
Group type: COMPARATOR
Intervention: mylohyoid nerve block + mock IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 30
Study 8622107 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily
Number of subjects: 130
Study 8622107 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily
Number of subjects: 130
Study 8622107 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily
Number of subjects: 130
Study 8622107 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 130
Study 2188770 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (10, 50, 150, and 500 IU/kg) administered intravenously
Number of subjects: 16
Study 2188770 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (1000 IU/kg) administered intravenously in an open manner
Number of subjects: 16
Study 2188770 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (various doses)
Number of subjects: 16
Study 2188770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6994369 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso‐Ameritrat (2.5 mg Isosorbide Dinitrate and 10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Number of subjects: 9
Study 6994369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ameritrat (10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Number of subjects: 9
Study 6994369 — intervention group
Group type: COMPARATOR
Intervention: Meprobamate (200 mg)
Number of subjects: 9
Study 31268377 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Perception of Birth Psychoeducation Program (TPBPP)
Number of subjects: 60
Study 31268377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 30258854 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percentage of daily energy intake from fats
Number of subjects: 257
Study 30258854 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percent of energy intake from proteins
Number of subjects: 257
Study 30258854 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percent of energy intake from carbohydrates
Number of subjects: 257
Study 27495373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail survey mode
Number of subjects: 2839
Study 27495373 — intervention group
Group type: COMPARATOR
Intervention: Telephone survey mode
Number of subjects: 2839
Study 27495373 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with lower educational attainment
Number of subjects: 2839
Study 27495373 — intervention group
Group type: COMPARATOR
Intervention: Caregivers with higher educational attainment
Number of subjects: 2839
Study 24374821 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐986001 (10, 30, 100, 300, 600, and 900 mg fed; 100 and 300 mg fasted)
Number of subjects: 64
Study 24374821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22083536 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal arm exercise
Number of subjects: 15
Study 22083536 — intervention group
Group type: COMPARATOR
Intervention: Maximal leg exercise
Number of subjects: 15
Study 19768533 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant docetaxel (75 mg/m2 on day 8) plus gemcitabine (1,000 mg/m2 on days 1 + 8) for 8 cycles
Number of subjects: 100
Study 19768533 — intervention group
Group type: COMPARATOR
Intervention: Sequential docetaxel (100 mg/m2 on day 1 for 4 cycles) followed by gemcitabine (1,250 mg/m2 on days 1 + 8 for 4 cycles)
Number of subjects: 100
Study 17689809 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic threshold technique (TT) for measuring maximum acceptable risk increments (MARI) for adverse effects from OA medication.
Number of subjects: 196
Study 16344838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (MAS XR) 10-60 mg/day (mean dose: 37.2 mg/day)
Number of subjects: 725
Study 12131384 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning Point: Rethinking Violence (TPRV) program
Number of subjects: 38
Study 12131384 — intervention group
Group type: COMPARATOR
Intervention: Standard court sentencing options (100 hours of community service)
Number of subjects: 38
Study 11488519 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 over 1 hour
Number of subjects: 18
Study 11488519 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m2 over 3 hours
Number of subjects: 18
Study 11488519 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paclitaxel and carboplatin
Number of subjects: 18
Study 10085709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Number of subjects: 24
Study 10085709 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hemodialysis treatment
Number of subjects: 24
Study 7759968 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIFT
Number of subjects: 60
Study 7759968 — intervention group
Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 60
Study 3190220 — intervention group
Group type: EXPERIMENTAL
Intervention: BDD supplemented with aspartame
Number of subjects: 59
Study 3190220 — intervention group
Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD)
Number of subjects: 59
Study 3190220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 59
Study 1098727 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 50 mg three times a day by mouth for three days every fortnight, starting three days before surgery
Number of subjects: 111
Study 1098727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 1098727 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 111
Study 1098727 — intervention group
Group type: COMPARATOR
Intervention: Levamisole and Placebo
Number of subjects: 111
Study 31689125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite population
Number of subjects: 302
Study 31689125 — intervention group
Group type: COMPARATOR
Intervention: White population
Number of subjects: 302
Study 30959470 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 460
Study 30959470 — intervention group
Group type: COMPARATOR
Intervention: Control arm (symptom management education)
Number of subjects: 460
Study 30959470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 460
Study 28629132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2800 IU daily for eight weeks)
Number of subjects: 200
Study 28629132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 25435541 — intervention group
Group type: EXPERIMENTAL
Intervention: Population screening (PS) arm
Number of subjects: 1017
Study 25435541 — intervention group
Group type: COMPARATOR
Intervention: Family history (FH) arm
Number of subjects: 1017
Study 25435541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PS and FH arms
Number of subjects: 1017
Study 25435541 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based genetic testing
Number of subjects: 1017
Study 22960949 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial optic neurotomy (RON)
Number of subjects: 83
Study 22960949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVT)
Number of subjects: 83
Study 22960949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21990403 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 6186
Study 21990403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 6186
Study 21990403 — intervention group
Group type: COMPARATOR
Intervention: Age ≥ 70 years
Number of subjects: 6186
Study 21990403 — intervention group
Group type: COMPARATOR
Intervention: Comorbidity score
Number of subjects: 6186
Study 19307225 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux treatment
Number of subjects: 0
Study 19307225 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scoring system
Number of subjects: 0
Study 16352871 — intervention group
Group type: EXPERIMENTAL
Intervention: on-line haemodiafiltration (oHDF)
Number of subjects: 70
Study 16352871 — intervention group
Group type: COMPARATOR
Intervention: haemodialysis (HD)
Number of subjects: 70
Study 15138682 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanatory Model Interview (EMIC)
Number of subjects: 87
Study 11294367 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg
Number of subjects: 28
Study 11294367 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg
Number of subjects: 28
Study 11294367 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg/fluticasone propionate 500 microg
Number of subjects: 28
Study 9148578 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) applied to 70 patients
Number of subjects: 115
Study 9148578 — intervention group
Group type: COMPARATOR
Intervention: Control group (without AT) consisting of 45 patients
Number of subjects: 115
Study 8458448 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) depot (Enantone Depot, Takeda, Italy) administered preoperatively
Number of subjects: 193
Study 8458448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LA depot)
Number of subjects: 193
Study 2429085 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (500‐1000 mg daily)
Number of subjects: 14
Study 2429085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30565854 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg day−1 for 4 weeks
Number of subjects: 245
Study 30565854 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 245
Study 30442608 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Relative Joint Displacement (3DRJDP) and 6D Symmetric Relative Joint Displacement (6DSymRJDP) features
Number of subjects: 45
Study 30442608 — intervention group
Group type: COMPARATOR
Intervention: Existing features focusing on individual joints
Number of subjects: 45
Study 24714541 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB-FA (3 g) and ATP (400 mg) supplementation
Number of subjects: 0
Study 24714541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24706266 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic bread (1 × 10(8) CFU Lactobacillus sporogenes and 0.07 g inulin per 1 g)
Number of subjects: 78
Study 24706266 — intervention group
Group type: COMPARATOR
Intervention: Probiotic bread (1 × 10(8) CFU Lactobacillus sporogenes per 1 g)
Number of subjects: 78
Study 24706266 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 78
Study 21450196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice intervention embedded in regular therapy
Number of subjects: 36
Study 21450196 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy as usual (control group)
Number of subjects: 36
Study 20450590 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-Magnesium infusion
Number of subjects: 93
Study 20450590 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH)
Number of subjects: 93
Study 20450590 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (normal saline)
Number of subjects: 93
Study 17364394 — intervention group
Group type: EXPERIMENTAL
Intervention: DAART (Directly Administered Antiretroviral Therapy)
Number of subjects: 250
Study 17364394 — intervention group
Group type: EXPERIMENTAL
Intervention: DAART
Number of subjects: 250
Study 15721975 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (physician feedback on physical activity level)
Number of subjects: 90
Study 15721975 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus group (further advice, stage matched leaflets, and a 45-min counselling session)
Number of subjects: 90
Study 15721975 — intervention group
Group type: COMPARATOR
Intervention: Both groups (feedback and advice plus)
Number of subjects: 90
Study 14500163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 40
Study 14500163 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 10325288 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection/ablation of visible endometriosis (54 patients)
Number of subjects: 101
Study 10325288 — intervention group
Group type: COMPARATOR
Intervention: No treatment (diagnostic laparoscopy only, 47 patients)
Number of subjects: 101
Study 8961453 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain facility treatment
Number of subjects: 236
Study 1763680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 0
Study 1763680 — intervention group
Group type: COMPARATOR
Intervention: Control (no immuno-suppressive treatment)
Number of subjects: 0
Study 6955993 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 14
Study 6955993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3902906 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine antiseptic (LA)
Number of subjects: 78
Study 29530858 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim (80 mg) administered intravenously every 12 h for 5 to 14 days
Number of subjects: 613
Study 29530858 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg of body weight) administered intravenously every 12 h for 5 to 14 days
Number of subjects: 613
Study 26560249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure guided management (treatment group)
Number of subjects: 550
Study 26560249 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 550
Study 26560249 — intervention group
Group type: COMPARATOR
Intervention: Open access to pulmonary artery pressure information for former control group
Number of subjects: 550
Study 25045258 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 1838
Study 25045258 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 1838
Study 25045258 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 1838
Study 25045258 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol
Number of subjects: 1838
Study 25045258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1838
Study 22116265 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament-retaining prostheses
Number of subjects: 60
Study 22116265 — intervention group
Group type: COMPARATOR
Intervention: Posterior cruciate ligament-sacrificing prostheses
Number of subjects: 60
Study 20546269 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemia (5.0 mmol/l)
Number of subjects: 7
Study 20546269 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycaemia (11.0 mmol/l)
Number of subjects: 7
Study 19034035 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 37.5 mg
Number of subjects: 54
Study 19034035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15907330 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel pads of diabetic subjects
Number of subjects: 40
Study 15907330 — intervention group
Group type: COMPARATOR
Intervention: Heel pads of nondiabetic subjects
Number of subjects: 40
Study 15907330 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically realistic heel-pad model
Number of subjects: 40
Study 11394468 — intervention group
Group type: EXPERIMENTAL
Intervention: ECU muscle pain
Number of subjects: 12
Study 11394468 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 9507380 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis initiated based on CD34+ blood level exceeding 20,000 CD34+/ml
Number of subjects: 0
Study 9507380 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis for high-level mobilizers (> 80,000 CD34+ cells/ml)
Number of subjects: 0
Study 9507380 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukapheresis for low-level mobilizers (< 40,000 CD34+ cells/ml)
Number of subjects: 0
Study 8064949 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine 12.5 mg + dapsone 100 mg)
Number of subjects: 100
Study 8064949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3376912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, carbohydrate-rich diet (total fat 22 en%) for 36 days
Number of subjects: 47
Study 3376912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, olive-oil-rich diet (oleic acid 24 en%, total fat 41 en%) for 36 days
Number of subjects: 47
Study 3376912 — intervention group
Group type: COMPARATOR
Intervention: Comparison between low-fat and high-fat diets
Number of subjects: 47
Study 30183875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture (Treatment)
Number of subjects: 110
Study 30183875 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 110
Study 30183875 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 110
Study 26659915 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1600/800 mg
Number of subjects: 0
Study 26659915 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 400/400 mg
Number of subjects: 0
Study 26659915 — intervention group
Group type: COMPARATOR
Intervention: Obinutuzumab 1000 mg fixed-dose regimen
Number of subjects: 0
Study 25042488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroprotector АРТРА with melaxen (melatonin 3 mg)
Number of subjects: 120
Study 25042488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroprotector АРТРА with melaxen (melatonin)
Number of subjects: 120
Study 25042488 — intervention group
Group type: COMPARATOR
Intervention: Chondroprotector АРТРА and diclofenac
Number of subjects: 120
Study 22119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous access for CS cannulation
Number of subjects: 0
Study 22119856 — intervention group
Group type: COMPARATOR
Intervention: Central venous access for CS cannulation
Number of subjects: 0
Study 22119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy time for CS cannulation
Number of subjects: 0
Study 20647201 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with zidovudine, lamivudine, and efavirenz therapy within 2 weeks after enrollment
Number of subjects: 816
Study 20647201 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment starting when CD4+ T-cell count fell to 200 or less or when clinical AIDS developed
Number of subjects: 816
Study 20647201 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with zidovudine, lamivudine, and efavirenz therapy
Number of subjects: 816
Study 18571088 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscodissection (Group 2)
Number of subjects: 14
Study 18571088 — intervention group
Group type: COMPARATOR
Intervention: Hydrodissection (Group 1)
Number of subjects: 14
Study 16003229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal (CSWD)
Number of subjects: 301
Study 16003229 — intervention group
Group type: COMPARATOR
Intervention: Chronic corticosteroid therapy (CCST)
Number of subjects: 301
Study 16003229 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid rejection therapy in CSWD patients
Number of subjects: 301
Study 11809343 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT 1 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every month)
Number of subjects: 321
Study 11809343 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT 2 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every third month)
Number of subjects: 321
Study 11809343 — intervention group
Group type: COMPARATOR
Intervention: No HRT (control group)
Number of subjects: 321
Study 11809343 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (both HRT 1 and HRT 2)
Number of subjects: 321
Study 10357496 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) with didanosine (ddI)
Number of subjects: 0
Study 10357496 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) with zalcitabine (ddC)
Number of subjects: 0
Study 10357496 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (AZT) alone
Number of subjects: 0
Study 7587243 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring devices
Number of subjects: 0
Study 7587243 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternatives to randomized, controlled trials
Number of subjects: 0
Study 7587243 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for device testing
Number of subjects: 0
Study 2225706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloprednol
Number of subjects: 39
Study 2225706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 39
Study 2225706 — intervention group
Group type: COMPARATOR
Intervention: Control (Beclomethasone)
Number of subjects: 39
Study 2225706 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (Postmenopausal women)
Number of subjects: 39
Study 2225706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloprednol (Postmenopausal women)
Number of subjects: 39
Study 848577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine with imipramine
Number of subjects: 55
Study 848577 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene with placebo
Number of subjects: 55
Study 30357395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP management (<120 mm Hg)
Number of subjects: 162
Study 30357395 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard SBP management (<140 mm Hg)
Number of subjects: 162
Study 30357395 — intervention group
Group type: COMPARATOR
Intervention: Control participants (no incident CKD)
Number of subjects: 162
Study 26700126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 537
Study 26700126 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-only
Number of subjects: 537
Study 25195125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin only
Number of subjects: 200
Study 25195125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine only
Number of subjects: 200
Study 25195125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine and atorvastatin
Number of subjects: 200